VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”),…
Revenue grew 336.5% to $14.4 million from prior year (excluding ACT Genomics)Raises full year revenue outlook to $80 - $100…
Revenue grew 336.5% to $14.4 million from prior year (excluding ACT Genomics)Raises full year revenue outlook to $80 - $100…
Revenue grew 336.5% to $14.4 million from prior year (excluding ACT Genomics)Raises full year revenue outlook to $80 - $100…
Company expected to resume trading on the NYSE American on Tuesday, June 17, 2025OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE)…
Company expected to resume trading on the NYSE American on Tuesday, June 17, 2025OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE)…
Company expected to resume trading on the NYSE American on Tuesday, June 17, 2025OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE)…
Data are being presented at the 30th Annual Congress of the European Hematology Association 2025 (EHA2025)WOBURN, Mass., June 12, 2025…
Data are being presented at the 30th Annual Congress of the European Hematology Association 2025 (EHA2025)WOBURN, Mass., June 12, 2025…
Data are being presented at the 30th Annual Congress of the European Hematology Association 2025 (EHA2025)WOBURN, Mass., June 12, 2025…